Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
100 shares to raise it 10pts. Close @ 0084
ASCM is there to short this back to low 0.003....I had high hope for a break over 1c...seems it was a fake breakout....
I am in long term. Not selling.
The chart since March of 21': https://www.barchart.com/stocks/quotes/HALB/interactive-chart
This is a stock you don't sell. Buy all you can and hold till it goes to the moon.
The day to sell was 2 days ago. Who really expected this second PR to take the price up?
Great Year-End CEO report. Halberd Corporation is for real. A lot to look forward to in 2024.
$HALB Halberd Corporation 2023 Year-End CEO Update and 2024 Goals
https://www.accesswire.com/823781/halberd-corporation-2023-year-end-ceo-update-and-2024-goals
JACKSON CENTER, PA / ACCESSWIRE / January 11, 2024 / Halberd Corporation (OTC PINK:HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023.
2023 ACHIEVEMENTS
Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary laser eradication methodology. Testing at Youngstown State University (YSU) successfully eradicated every sample of the various strains of E. coli, Candida auris, Shigella, and Klebsiella pneumoniae, which are linked to numerous infections, including pneumonia, meningitis, digestive tract infections, etc.
Eradication of these bacteria was achieved by using as little as 10% of the laser power used in the initial eradication testing. The ability to achieve the same level of antigen eradication at a fraction of the power further reduces potential collateral damage to surrounding constituents in blood or CSF
Halberd contracted Mississippi State University (MSU) to develop and conduct a preclinical testing protocol for Halberd's patent-pending nasal spray to safely counteract the effects of Traumatic Brain Injury (TBI).
This testing at MSU demonstrated the efficacy of our nasal spray by significantly reducing key neuronal damage biomarkers by as much as 50%! The timely application of Halberd's nasal spray within hours of a traumatic brain injury may potentially mitigate factors associated with long-term neurodegeneration, often leading to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. This product, with its capacity for more immediate application effectiveness than any other known alternative, uniquely positions Halberd to timely and effectively reduce inflammatory cytokines and excitatory neurotransmitters to avoid the irreversible damage of TBI.
Halberd prepared and submitted seven Abstracts to the government's ARPA-H (Advance Research Projects Agency - Health) website for contract consideration. These were recommended by ARPA-H for consideration by the military, where selection decisions are pending.
MSU collected tissue samples from the TBI mitigating nasal spray test subjects for histopathology analysis to quantify the presence of TBI biomarkers.
Halberd signed a collaboration agreement with Athena GTX to cooperate on submissions to government agencies for the development of detection and treatment of TBI as a point-of-injury application.
Based on the successful initial testing results of Halberd's nasal spray at MSU, Halberd requested MSU to submit a proposal to conduct an expanded sample test project to replicate the initial test with a larger sample size.
Late in the 4th quarter, Halberd and CrodenHealth Corp. of Canada reached an agreement for CrodenHealth to produce, market, sell and distribute Halberd's patented low dose naltrexone (LDN+) products.
During the course of the year, Halberd added to its intellectual property and now has accumulated four issued patents and 22 patents pending, indicating an extremely strong research capability.
THE LOOK AHEAD
Prior work revealed potential corporate needs associated with the need for non-dilutive funding to expand and continue:
Antibody/antigen R&D at YSU, fine-tuned for maximum efficacy;
Extension of animal testing at MSU on Halberd's patent-pending TBI Nasal Spray, including conforming it to FDA requirements
Completion of clinical trials of Halberd's patented LDN+ Drug and TBI Nasal Spray products;
FDA certification of both LDN+ and TBI Nasal Spray products, and
Applications for government contracts for both of Halberd's most promising near-term prospects for commercial success: LDN+ and TBI Nasal Spray
The BEST NEWS- - We have secured non-dilutive funding for all of the above, along with assistance in pursuing government contracts via a joint venture with Athena GTX, an established government contractor with a proven history of identifying government needs and obtaining contracts to fill those needs.
Halberd will continue its work at YSU and MSU during 2024, and coordinate prototype clinical trials with CrodenHealth and Athena GTX with an aim toward FDA approval and marketing.
Halberd will meet with the Center for Disease Control (CDC) early in 2024 to review our stunning success in eradicating all 60 strains of antibiotic-resistant bacteria and Candida Auris Fungi supplied by the CDC. Results to date have been accomplished using our patented laser process as well as the success of our previously unannounced proprietary process of utilizing pre-processed nanoparticles to minimize collateral damage for blood-borne diseases. We believe that the CDC will be very interested in the success of our pre-processing experimentation.
We plan to complete a thorough financial audit in 2024 and, pending stock price enhancement, file for fully reporting status
Following successful clinical trials with the military of Halberd's most promising near-term products (LDN+ and TBI Nasal Spray), FDA certification and commercialization prospects will be guided with the active consultation of Dr. Mark Darrah, CEO of Athena GTX, and Peter Croden, Chairman of CrodenHealth and former president of Upjohn/Pfizer Canada and later of Upjohn/Pfizer Animal Health, headquartered in Kalamazoo, Michigan.
SUMMARY
Throughout 2023, Halberd management continued to guide technological advancements. Halberd's success was demonstrated by the ability of its proprietary single antibody, coupled with its patent-pending laser methodology, to effectively eradicate multiple strains of antibiotic-resistant bacteria and fungi. We believe that our decision to focus on expansion of our R&D from antibody/antigen treatment to include LDN+ and nasal spray products will prove to be a major benefit to both the short- and long-term interests of the company and its stockholders. Recent developments and interest by the military have proven the validity of that decision.
We believe in our mission, to create and develop safe and effective treatments against many previously perceived incurable and hard-to-treat diseases and to continue our progress towards achieving that goal. For the near-term, we remain focused on the most promising of our technologies with particular focus on those products with the shortest development time, and they include:
Our patented LDN+ drug that can be an effective medication against pain, anxiety, PTSD, suicidal ideation, and chemical and alcohol addiction, and
Our patent-pending nasal spray that mitigates the potential neurodegenerative cascade following head trauma.
We believe that both technologies have the potential to be multi-billion-dollar market products, in the relatively short-term, and our belief is shared by our two recent joint venture partners, who have pledged to support us financially and with their expertise in our efforts continuing into 2024.
In summary, 2023 has been an extremely successful year! We have exceeded all of our goals associated with establishing a non-dilutive funding source for our continuing R&D at Youngstown State University and Mississippi State University.
We secured experienced assistance in dealing with the military, secured interest by the military in our breakthrough technologies, while establishing the basis for initial clinical trials paid by the military; secured experienced senior consultants who will guide us through the FDA certification process; and secured a senior partner with significant first-hand relationships with Big Pharma.
We also appreciate the efforts of our expanding team of research scientists, and the support of our stockholders. We will continue to maintain transparency and pledge to improve our communication with our family of interested parties. Watch us closely as we intend to move our development along at a very fast pace in 2024. We expect even greater accomplishments in 2024, because we now have the tools to efficiently complete the job and the experience to competently guide us.
If you know of somebody who would be interested in receiving no-cost e-mail copies of our press releases and quarterly CEO letters directly to their computer/telephone in-box, please send us their e-mail address (with their permission), and we will add them to our expanding family of followers.
CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Press Release | 01/10/2024
Correction: The initial release stated Mr. Peter Croden was previously Global President of Upjohn/Pfizer Animal Health Division in Germany. The Animal Health Division is located in Kalamazoo, Michigan. We are sorry for any confusion this may have caused.
Athena will employ its successful history of securing government contracts, spearheading such initiatives
JACKSON CENTER, PA / ACCESSWIRE / January 10, 2024 / Halberd Corporation (OTC-PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Athena's 20+ year history of innovative research and development funding from the government (representing 60% of its income historically) in terms of multi-year contracts and grants, and specifically, novel military products and services averaged about $4-5 million per year with substantial growth still ongoing in these markets. This agreement aligns Athena GTX's proven expertise and vast connections with breakthrough Intellectual property owned by Halberd. Together, their 2024 aggressive development plans include rapid release of products into a market Halberd has not been able to tap into for both Halberd's innovative Traumatic Brain Injury (TBI) nasal spray therapy and LDN+ for Post Traumatic Stress Disorder (PTSD), suicidal ideation, pain, anxiety, and drug/alcohol addiction common in returning veterans. This, according to new highly exciting government proposals, suggests an enormously exciting year ahead, particularly with the feedback received from these agencies.
Dr. Mark Darrah, CEO of Athena, stated; "The combination of ongoing University research on Halberd's unique concept products today, with very credible preliminary results, and the enormous market demands we serve, is a natural win-win for both companies. Our plan is to bolster funding in these efforts, capture new research dollars from the government, and push the technology solutions through the FDA and into vertical markets expeditiously. These product solutions dovetail nicely into what we do now and whom we serve. I could not be more pleased!
Recent business analyses detailed our five-year plan forward documenting a compelling market demand and overall an $80 billion potential diversified market expanding at impressive annual growth rates. With Athena's 2024-2026 revenue projections nearly doubling, the Athena partnership with Halberd now represents unparalleled growth projections for both companies."
Peter Croden, Chairman of the Board of CrodenHealth Corp. (another new joint venture partner of Halberd) and former President of Upjohn/Pfizer Canada as well as later Global President of Upjohn/Pfizer Animal Health Division, headquartered in Kalamazoo Michigan, stated, "CrodenHealth Corp. is looking forward to a very successful relationship with Athena GTX and the Halberd Corporation. And, yes, it is going to be a great year in 2024!!."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, added, "Beginning 2023, the task ahead looked daunting- - Halberd needed seven key elements in order to seriously plan for future commercial applications for our technology products, and these were:
Research funding for our base antibody/antigen experimentation at Youngstown State University;
Research funding for our continuing animal testing at Mississippi State University;
Funding for potential clinical trials of our patented LDN+ drug and our patent-pending TBI nasal spray;
Funding for potential FDA certification testing of both products;
Knowledge of how to work with the military and a reputation as a qualified supplier with the purchasing agents at the military agencies;
Experience in launching biomedical products into the market; and
Contacts with Big Pharma for potential future ventures and a potential eventual lucrative buyout.
I can safely say that we have secured all of the desired elements with our newly announced ventures with CrodenHealth Corp and Athena GTX. It has taken many months to put this master plan into form, but we have finally assembled the perfect team. We expect great things to happen rather quickly in 2024 because some of the advanced steps have already been initiated. More news to be issued shortly."
To get the latest
on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Athena GTX, Inc.
Athena GTX is a certified DoD small business with Corporate Headquarters in Johnston, Iowa. Athena focuses development on wearables and highly mobile, wirelessly connected monitoring technologies, and transitioning those to key markets to meet unmet needs of first responders worldwide. Wireless Patient Monitoring - Athena GTX connects patient and provider About - Athena GTX® Inc.
About CrodenHealth Corp
"We help scale amazing companies!"SM
CrodenHealth Corp. is a powerful modern team in healthcare. CrodenHealth Corp ensures clients achieve profitable growth through branding, strategic marketing, & tailored go to market strategies. With an exceptional team of marketing and industry experts, we collaborate with our clients to develop or optimize strategies and support successful implementation while maximizing return on investment (ROI).
See: http://crodenhealth.com/
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are
arket Cap Market Cap
5,858,748
01/09/2024
"With Athena's 2024-2026 revenue projections nearly doubling, the Athena partnership with Halberd now represents unparalleled growth projections for both companies." :)
Awesome close will only get better
Here's an interesting read for anyone who wants to know the link between HALB, BIEI and Marv LLC.
https://www.sec.gov/Archives/edgar/data/1515740/000165495420005442/biei_ex102.htm
And since Athena GTX already has the history and accomplishments with our government for funding, our CEO states " The best route is to take it through the military, where testing can be at government expense and certification can be shortened. That is our current plan, and we are just beginning the process to work with the military to that end.
Thanks for your interest in Halberd Corporation and our products. "
Hey maybe that's why they sealed the deal with Athena GTX?
:)
The last sentence reads: 'More news shortly'. Cha Ching.
Too bad ASCM is sitting there, ready to dump. Hopefully, he'll let it breath a bit.
(Thought it was going to be GTSM, but now looks more like ASCM)
$HALB Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
https://www.accesswire.com/823011/halberd-corp-signs-significant-revenue-sharing-agreement-with-athena-gtx
Athena will employ its successful history of securing government contracts, spearheading such initiatives
JACKSON CENTER, PA / ACCESSWIRE / January 9, 2024 / Halberd Corporation (OTC PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Athena's 20+ year history of innovative research and development funding from the government (representing 60% of its income historically) in terms of multi-year contracts and grants, and specifically, novel military products and services averaged about $4-5 million per year with substantial growth still ongoing in these markets. This agreement aligns Athena GTX's proven expertise and vast connections with breakthrough Intellectual property owned by Halberd. Together, their 2024 aggressive development plans include rapid release of products into a market Halberd has not been able to tap into for both Halberd's innovative Traumatic Brain Injury (TBI) nasal spray therapy and LDN+ for Post Traumatic Stress Disorder (PTSD), suicidal ideation, pain, anxiety, and drug/alcohol addiction common in returning veterans. This, according to new highly exciting government proposals, suggests an enormously exciting year ahead , particularly with the feedback received from these agencies.
Dr. Mark Darrah, CEO of Athena, stated; "The combination of ongoing University research on Halberd's unique concept products today, with very credible preliminary results, and the enormous market demands we serve, is a natural win-win for both companies. Our plan is to bolster funding in these efforts, capture new research dollars from the government, and push the technology solutions through the FDA and into vertical markets expeditiously. These product solutions dovetail nicely into what we do now and whom we serve. I could not be more pleased!
Recent business analyses detailed our five-year plan forward documenting a compelling market demand and overall an $80 billion potential diversified market expanding at impressive annual growth rates. With Athena's 2024-2026 revenue projections nearly doubling, the Athena partnership with Halberd now represents unparalleled growth projections for both companies."
Peter Croden, Chairman of the Board of CrodenHealth Corp. (another new joint venture partner of Halberd) and former President of Upjohn/Pfizer Canada as well as later Global President of Upjohn/Pfizer Animal Health Division in Germany, stated, "CrodenHealth Corp. is looking forward to a very successful relationship with Athena GTX and the Halberd Corporation. And, yes, it is going to be a great year in 2024!!."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, added, "Beginning 2023, the task ahead looked daunting- - Halberd needed seven key elements in order to seriously plan for future commercial applications for our technology products, and these were:
Research funding for our base antibody/antigen experimentation at Youngstown State University;
Research funding for our continuing animal testing at Mississippi State University;
Funding for potential clinical trials of our patented LDN+ drug and our patent-pending TBI nasal spray;
Funding for potential FDA certification testing of both products;
Knowledge of how to work with the military and a reputation as a qualified supplier with the purchasing agents at the military agencies;
Experience in launching biomedical products into the market; and
Contacts with Big Pharma for potential future ventures and a potential eventual lucrative buyout.
I can safely say that we have secured all of the desired elements with our newly announced ventures with CrodenHealth Corp and Athena GTX. It has taken many months to put this master plan into form, but we have finally assembled the perfect team. We expect great things to happen rather quickly in 2024 because some of the advanced steps have already been initiated. More news to be issued shortly."
Don’t like to speculate but statically dollar land in halberd isn’t theoretical anymore or taboo!!! It is tangible
And this is just the TBI program. Virus elimination project is upcoming.
I got that from our CEO relating to the nasal spray. He has a mission and he is using many avenues to get there. :)
"The best route is to take it through the military, where testing can be at government expense and certification can be shortened. That is our current plan, and we are just beginning the process to work with the military to that end." I can wait. :)
Great tweet ! It seems that Shits going to get real hot in here !
Doesn't matter. He doesn't own, he just bitches on companies for a hobby. To each is own. :)
HALB: I will NEVER be a "significant" announcement from this SCAMMING circus sideshow. MARK IT!!!!
I've got over 2.5 mil waiting for glory. :)
It's not Halberds typical type of tweet.
Who knows. I just know when a company puts out a tweet that basically says significant news early this week, it's worth a bet. Just read the tweet.
$HALB - "Stay tuned for two significant announcements from $HALB early this week!"
Stay tuned for two significant announcements from $HALB early this week!
— Halberd Corporation (@HalberdC) January 8, 2024
CHECK Twitter:
Halberd Corporation
@HalberdC
Stay tuned for two significant announcements from $HALB early this week!
1:44 PM · Jan 8, 2024
·
224 Views
Bring it on , not too many eyes on this one , it’s a hidden GEM
And it will be even bigger when the 'NEWS' comes out.
yes it is$$$$$$$$$$$$$
BUSINESS DESCRIPTION
Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurological and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid extracorporeally, or outside the body. Disease eradication occurs when designed disease-specific antibodies conjoined with metallic nanoparticles come in contact with disease antigens, and the resultant conjoined antibody/nanoparticle/antigen moiety are then exposed to radio frequency, laser irradiation, or chemical bonding and are destroyed. The cleansed bodily fluids are then returned to the patient without deadly side effects associated with injected or ingested medications.Halberd's technology base consists of four issued patents and 22 pending patents: Projects with potential submission to government/military agencies include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma
If it drops at the 0.0039ish level, I am going to consider to add more, otherwise, I am famished with my underwater position, let it be
OTC DISCLOSURE & NEWS SERVICE
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
Press Release | 12/13/2023
Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to move Halberd forward
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2023 / Halberd Corporation (OTC PINK:HALB) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd's patented low dose naltrexone combo product(s) worldwide. The agreement also allows CrodenHealth.com right of first refusal regarding similar rights to future products in Halberd's development pipeline.
Peter Croden, Chairman of the Board of CrodenHealth, enjoys a long history in the pharmaceutical industry- over 30 years with Upjohn & Pharmacia Corp. (now Pfizer) in various senior management roles, including President and General Manager of Upjohn Canada and later, President Upjohn Worldwide Animal Health. In 2001, Mr. Croden launched the biotechnology company, NephRx as CEO. In 2015, Mr Croden was appointed to the Board of Parnell Pharmaceuticals Holdings, Ltd.
Peter Croden, together with his son, Brad Croden, and nephew, Todd Croden, have over five decades of experience in the pharmaceuticals industry, culminating in the management of CrodenHealth.com. CrodenHealth's role with Halberd Corporation will include efforts to facilitate industry joint ventures and funding as well as drug certification efforts.
Brad Croden, CEO of CrodenHealth, commented, "We are excited to monetize the amazing current & future intellectual property (products) of Halberd Corporation; creating new & profitable revenue streams. This new agreement marks the beginning of a long fruitful win-win relationship between CrodenHealth & Halberd Corporation."
Peter Croden added, "With CrodenHealth's vast pharmaceutical sales & marketing expertise and Halberd Corporations unique groundbreaking intellectual property & first-to-market products - will ensure a profitable positive impact on patient outcomes."
William A. Hartman, Chairman, President, and CEO of Halberd Corporation, commented, "Given the commitment of CrodenHealth, coupled with the principals' vast network of relationships and past dealings with large pharmaceutical companies, they have the wherewithal to facilitate game changing joint ventures. These relationships, should also inure to the benefit of Athena GTX and complements many of Halberd's other efforts in the medical field. They also enhance Halberd's capacity to fulfill its commitments to the various military organizations which have specifically expressed interest in one or more of Halberd's endeavors. CrodenHealth also has access to unique applications of bio-marker artificial intelligence in various medical applications."
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
About CrodenHealth.com
"We help scale amazing companies!"SM
CrodenHealth is a powerful modern team in healthcare. CrodenHealth ensures clients achieve profitable growth through branding, strategic marketing, & tailored go to market strategies. With an exceptional team of marketing and industry experts, we collaborate with our clients to develop or optimize strategies and support successful implementation while maximizing return on investment (ROI).
See: http://crodenhealth.com/
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), a publicly traded entity on the OTC Market, adheres fully to OTC Market reporting regulations. Following its restructuring in April 2020, Halberd secured exclusive global rights to three granted patents and submitted 22 associated provisional, PCT, or utility patent
(responsible mod: Bill Moynihan/EHRjunkie)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |